![](/images/graphics-bg.png)
Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
المؤلفون المشاركون
Liu, Zhiguang
Zhang, Guanqun
Zhu, Liang
Wang, Jiangbo
Liu, Dongbo
Lian, Lifei
Liu, Jianlin
Lai, Tianbao
Zhuang, Xiaorong
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-02-18
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
The aim of this study was to assess the activity and safety of bevacizumab (BEV) and fotemustine (FTM) for the treatment of recurrent glioblastoma multiforme (GBM) patients and explore the potential prognostic parameters on survival.
This study retrospectively analyzed all patients with GBM who were treated with at least one cycle of BEV and FTM from July 2010 to October 2012.
A total of 176 patients with recurrent GBM were enrolled.
The response rate and disease control rate were 46.6% and 90.9%, respectively.
A 6-month PFS rate of 33.3% (95% CI: 26.5%–40.3%) and a median PFS of 5.0 (95% CI: 2.4–7.5) months were observed.
The median OS was 8.0 (95% CI: 6.7–9.2) months.
Multivariate analysis showed that risk factors with a significant influence on the PFS of all patients were Karnofsky Performance Status (KPS) (≥70 versus <70, HR=0.53, 95% CI: 0.39–0.73, and P=0.01) and MGMT status (methylated versus unmethylated, HR=0.69, 95% CI: 0.52–0.97, and P=0.04).
The most common treatment-related adverse events were fatigue, proteinuria, hypophonia, hypertension, thrombocytopenia, anemia, and neutropenia.
In conclusion, combination of BEV with FTM is well tolerated and may derive some clinical benefits in recurrent GBM patients.
Higher KPS and MGMT promoter hypermethylation were suggested to be associated with prolonged survival.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Liu, Zhiguang& Zhang, Guanqun& Zhu, Liang& Wang, Jiangbo& Liu, Dongbo& Lian, Lifei…[et al.]. 2015. Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme. BioMed Research International،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1056510
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Liu, Zhiguang…[et al.]. Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme. BioMed Research International No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1056510
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Liu, Zhiguang& Zhang, Guanqun& Zhu, Liang& Wang, Jiangbo& Liu, Dongbo& Lian, Lifei…[et al.]. Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1056510
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1056510
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)